For citations:
Ananyeva L.P., Lila A.M., Gaydukova I.Z., Abdulganieva D.I., Starovoytova M.N., Lukina G.V., Porozova A.A., Eremeeva A.V., Pukhtinskaia P.S., Nasonov E.L. The impact of clinical and demographic factors on the efficacy of divozilimab in patients with systemic sclerosis: Post hoc analysis of the randomized, double-blind, placebo-controlled phase III clinical trial LIBERIUS. Rheumatology Science and Practice. 2025;63(6):619-628. (In Russ.) https://doi.org/10.47360/1995-4484-2025-619-628
JATS XML































